NCT05244148终止不适用
A Multicentre, Randomised, Open Label, Parallel Group, Controlled Clinical Trial to Evaluate Efficacy and Tolerability of Two Seawater-based Formulations Plus a Standard of Care Versus the Standard of Care Alone for Relief of Nasal Congestion in Paediatric Subjects With Common Cold
Church & Dwight Company, Inc.2 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2021年11月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Change of nasal congestion.
研究概览
简要总结
The objective of this clinical trial is to evaluate the tolerance and efficacy of two Stérimar nasal sprays products in children who have nasal congestion due to the common cold.
详细描述
This clinical trial is a multicentre, randomized, parallel-group, controlled, open-label clinical trial to evaluate the efficacy of two Stérimar nasal sprays formulations (medical device already CE marked) for nasal congestion in children aged 3 to 48 months with common cold. In total the study foresees 300 patients divided between the different clinical sites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Months 至 48 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female infants and toddlers aged 3 - 48 months (inclusive) at enrolment (Day 0).
- •Caretaker(s) answering "yes" to the question "Do you feel that your child has a cold?" at enrolment (Day 0).
- •Subjects with symptoms started within 48 hours prior to enrolment (Day 0).
- •Subjects with nasal congestion (blocked / stuffy nose) rated as at least grade 2 (moderately bothersome) on a 0 to 2-point scale, based on morning evaluation (within an hour of subject awakening).
- •Subjects showing at least grade 2 on a 0 to 2-point scale for at least one of the following additional signs of cold symptoms: runny nose, nasal crust (dry mucus), thick mucus, sneezing and cough.
- •Legal caretaker(s) signed written informed consent for their young ones to participate in the study.
- •Legal caretaker(s) willing to comply with all study procedures.
- •Ability of the caretaker(s) (in the Investigator's opinion) to comprehend the full nature, procedures, and purpose of the study.
排除标准
- •Subjects presenting a body temperature greater than 38°C measured with a non-contact infrared thermometer at enrolment (Day 0).
- •Subjects presenting any secondary infection (such as bronchitis, otitis, tracheitis, pneumonia, and so on) at enrolment (Day 0).
- •Subjects with positive results on a streptococcal antigen screening test (rapid antigen detection test or RADT) at enrolment (Day 0).
- •Subjects with history of allergic rhinitis.
- •Subjects presenting any congenital or chronic disease that in the opinion of the Investigator would adversely affect the results of the study (e.g., asthma, pneumonia, laryngotracheobronchitis, sinusitis, and so on).
- •Subjects presenting any kind of immunodeficiency.
- •Subjects presenting any hypersensitivity or allergy or intolerance to any component of the study products.
- •Subjects with a positive medical history to any significant illness within the 2 weeks prior to the enrolment (Day 0).
- •Subjects presenting any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study.
- •Subjects currently participating or having participated in another clinical trial during the last 30 days prior to enrolment (Day 0).
- •Subjects using saline nose drops or nasal sprays or pumps other than the study products, antibiotics, antivirals, intranasal medicines, decongestants, antihistamines, echinacea, combination cold formulas, supplements containing ≥ 10 mg zinc that would influence symptoms scores at enrolment (Day 0) within 12 hours prior the day of screening.
结局指标
主要结局
Change of nasal congestion.
时间窗: Through study completion, an average of 10 days
Assess change of nasal congestion, evaluated by means of a specific questionnaire ("Cold Symptom Severity" questionnaire), to be completed at Day 0 (baseline) and daily from the beginning to the end of the study; comparisons among groups A, B versus group C.
次要结局
- Occurrence of secondary infections.(Daily through the end of the study, approximately 10 days)
- Change of other cold symptoms.(Through study completion, an average of 10 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Efficacy of Two Nasal Products Based on Diluted Seawater in the Treatment of Upper Respiratory Infections/ConditionsSinusitisUpper Respiratory InfectionsColdsRhinitisNCT06498843YSLab89
已完成
3 期
Study In Adults And Adolescents With Seasonal Allergic RhinitisHayfeverRhinitis, Allergic, SeasonalSeasonal Allergic RhinitisNCT00115622GlaxoSmithKline304
已完成
2 期
7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic RhinitisRhinitis, Allergic, SeasonalNCT00115089Rigel Pharmaceuticals375
已完成
2 期
Acute Treatment Trial in Adult Subjects With MigrainesMigraineNCT03872453Pfizer2,154
已完成
4 期
A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic RhinitisRhinitis, Allergic, PerennialNCT00609674GlaxoSmithKline315